Announced

Completed

Hologic completed the acquisition of Diagenode for $159m.

Synopsis

Hologic, a women's health company, completed the acquisition of Diagenode, a European developer and manufacturer of molecular diagnostic assays and epigenetics products, for $159m. “Acquiring Diagenode further strengthens our molecular diagnostics business by expanding our international capabilities, improving our regional time-to-market, and allowing us to offer a broader, more differentiated test menu,” Jan Verstreken, Hologic Group President.

Principals

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Sort

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US